{"id":"emorfazone","rwe":[{"pmid":"14572856","year":"2003","title":"4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity.","finding":"","journal":"Farmaco (Societa chimica italiana : 1989)","studyType":"Clinical Study"},{"pmid":"8169774","year":"1994","title":"[Studies on pyridazinone derivatives. XVI. Analgesic-antiinflammatory activities of 3(2H)-pyridazinone derivatives].","finding":"","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","studyType":"Clinical Study"},{"pmid":"1545477","year":"1992","title":"Double blind study on emorfazone and ibuprofen in dental pain and inflammation.","finding":"","journal":"JPMA. The Journal of the Pakistan Medical Association","studyType":"Clinical Study"},{"pmid":"3265150","year":"1988","title":"Analgesic action of amfenac Na, a non-steroidal anti-inflammatory agent.","finding":"","journal":"Journal of pharmacobio-dynamics","studyType":"Clinical Study"},{"pmid":"3203412","year":"1988","title":"Photochemical oxidation of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (Emorfazone) by pyrimido[5,4-g]pteridine 5-oxide. An attempt to apply a functional chemical model for biological oxidations to drug-metabolism studies.","finding":"","journal":"Chemical & pharmaceutical bulletin","studyType":"Clinical Study"}],"tags":[{"label":"emorfazone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Pain","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EMORFAZONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:53:40.403048+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:54:13.169319+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:53:47.813569+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EMORFAZONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:53:50.916137+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103954/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:53:51.621491+00:00"}},"allNames":"nandron","offLabel":[],"synonyms":["emorfazone","nandron","pentoil","pentoyl","M 73101","M73101"],"timeline":[],"aiSummary":"Emorfazone (Nandron) is a marketed drug primarily indicated for pain management, leveraging a unique mechanism of action that modulates pain perception through specific cellular interactions. The key composition patent for Emorfazone is set to expire in 2028, providing a clear period of market exclusivity and potential revenue stability. However, the lack of detailed revenue data and key trial results poses a significant risk in assessing the drug's long-term market performance and competitive positioning.","approvals":[{"date":"","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Nandron","ecosystem":[{"indication":"Pain","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"bromfenac","slug":"bromfenac","company":"Bausch And Lomb Inc"},{"name":"butorphanol","slug":"butorphanol","company":""},{"name":"caffeine","slug":"caffeine","company":"Novartis"}],"globalPrevalence":1500000000}],"mechanism":{"modality":"Small Molecule","drugClass":"emorfazone","explanation":"","oneSentence":"","technicalDetail":"The exact mechanism of action of Nandron is unknown, but it is believed to involve the modulation of pain perception through interactions with specific cellular targets, potentially including ion channels, receptors, or other signaling molecules."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1002","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EMORFAZONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:59:03.145145","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:54:13.169420+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"emorfazone","indications":{"approved":[{"name":"Pain","source":"DrugCentral","snomedId":22253000,"regulator":"FDA","usPrevalence":51600000,"globalPrevalence":1500000000,"prevalenceMethod":"curated","prevalenceSource":"CDC, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010918","UNII":"V93U9DH62C","CHEBI":"CHEBI:31535","INN_ID":"4942","UMLSCUI":"C0059081","chemblId":"CHEMBL2103954","ChEMBL_ID":"CHEMBL2103954","KEGG_DRUG":"D01353","PUBCHEM_CID":"3221","MESH_SUPPLEMENTAL_RECORD_UI":"C018432"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":10,"therapeuticAreas":["Pain"],"biosimilarFilings":[],"recentPublications":[{"date":"2003 Nov","pmid":"14572856","title":"4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity.","journal":"Farmaco (Societa chimica italiana : 1989)"},{"date":"1994 Feb","pmid":"8169774","title":"[Studies on pyridazinone derivatives. XVI. Analgesic-antiinflammatory activities of 3(2H)-pyridazinone derivatives].","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan"},{"date":"1992 Jan","pmid":"1545477","title":"Double blind study on emorfazone and ibuprofen in dental pain and inflammation.","journal":"JPMA. The Journal of the Pakistan Medical Association"},{"date":"1988 Sep","pmid":"3265150","title":"Analgesic action of amfenac Na, a non-steroidal anti-inflammatory agent.","journal":"Journal of pharmacobio-dynamics"},{"date":"1988 May","pmid":"3203412","title":"Photochemical oxidation of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (Emorfazone) by pyrimido[5,4-g]pteridine 5-oxide. An attempt to apply a functional chemical model for biological oxidations to drug-metabolism studies.","journal":"Chemical & pharmaceutical bulletin"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:54:13.169420+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}